The intrinsic apoptotic pathway is characterized by the release of several mitochondrial intermembrane proteins into the cytosol of dying cells. It is unclear whether the release of these proteins follows a common or specific pathway. In the present report we show that survivin and, to a lesser extent, the survivin splice variant survivin DeltaEx3 regulate the specific liberation of second mitochondria-derived activator of caspase/direct IAP binding protein with low pI (Smac/DIABLO), an inhibitor of apoptosis proteins binding protein, during apoptosis induced by etoposide, a DNA damaging agent. This antineoplastic drug induced posttranscriptional upregulation of survivin and survivin DeltaEx3. In turn, mitochondrial survivin associated with Smac/DIABLO, delaying its release. In addition, cytosolic survivin also stabilized the cytosolic levels of released Smac/DIABLO. These results provide an explanation for the observed differences in the release of mitochondrial intermembrane proteins in various apoptotic models and present a new mechanism for the anti-apoptotic effects of survivin in cancer cells.
Introduction
Apoptosis is a highly conserved cell suicide program essential for development and homeostasis of all metazoan organisms. One of the main routes to cell death is the mitochondrial or intrinsic pathway, mediated by the release of cytochrome c into the cytosol. Cytochrome c then binds to Apaf-1 and activates caspase 9, which in turn activates the effector caspases 3, 6 and 7. The cascade activation of caspases is strictly regulated, both positively and negatively. Members of the inhibitor of apoptosis proteins (IAP) family, which includes NAIP, cIAP1, cIAP2, XIAP, survivin, ML-IAP and BRUCE, bind to caspases and neutralize their activity. In turn, second mitochondria-derived activator of caspase (Smac), also known as direct IAP binding protein with low pI (DIABLO), binds and neutralizes IAPs, restoring caspase activity (Verhagen and Vaux, 2002) . After an apoptotic stimulus, Smac/ DIABLO is released into the cytosol where it neutralizes IAPs and potentiates apoptosis (Du et al., 2000) . In addition, the interaction between Smac/DIABLO and IAPs induces the proteasomal degradation of the former, due to the E3 ubiquitin protease ligase activity of the RING domain of cIAP-1, cIAP-2 and XIAP (Morizane et al., 2005) .
Although it is known that Smac/DIABLO is controlled by the Bcl-2 family of proteins (Yamaguchi et al., 2003) and mitogen-activated protein kinase family members such as Erk1/2 (Zhang et al., 2003) and c-Jun NH 2 -terminal kinase (Chauhan et al., 2003) , the precise mechanism and kinetics for release of Smac/ DIABLO from the mitochondria remain unclear. It has been reported both that Smac/DIABLO is released independently of cytochrome c (Deng et al., 2002) and simultaneously with it (Zhou et al., 2005) . This discrepancy might be the result of different mechanisms of release after a specific stimulus that eventually converge, as suggested by the requirement of caspase activity for Smac/DIABLO release but not for cytochrome c release (Adrain et al., 2001) . Alternatively, the release mechanism may be common, but additional input signals might retain Smac/DIABLO or cytochrome c specifically in the mitochondria. Here we report that survivin mediates a mitochondrial signal that prevents Smac/DIABLO release from mitochondria.
Results

Induction of apoptosis in HeLa cells by etoposide or staurosporine
To gain more insight into the regulation of cytochrome c and Smac/DIABLO release, we chose two different cell death stimuli that engage the intrinsic pathway: a DNA damaging agent, etoposide, and a drug that induces cellular stress, staurosporine. As shown in Figure 1 , cell death induced by these drugs was due to apoptosis, as both drugs induced typical apoptotic morphology with appreciable cytoplasmic condensation and nuclear fragmentation. Figure 1c shows that more caspase 9 and 7 were processed after exposure to etoposide than after exposure to staurosporine. In contrast, higher amounts of caspases 8 and 3 were cleaved after staurosporine exposure. The relative amount of caspase 7 cleavage by the two stimuli was reflected in the amount of fragmented poly-(ADP-ribose)polymerase protein, a substrate for this enzyme (Figure 1c) .
DNA damage and cell stress induce differential release of Smac/DIABLO and cytochrome c The differences in caspase processing following etoposide or staurosporine exposure suggested a divergence in the activation of the intrinsic apoptotic pathway. To assess this possibility, we analysed the release of Smac/ DIABLO and cytochrome c after exposure to etoposide or staurosporine. Even when the LD 50 was used for each drug, less cytochrome c and Smac/DIABLO was released in cells exposed to etoposide (Figure 2a ). It is important to note that even when a larger amount of Smac/DIABLO was released from the mitochondria in response to staurosporine, its cytosolic level did not increase (Figure 2b ), possibly due to rapid cytosolic degradation, as reported elsewhere (MacFarlane et al., 2002) . This was supported by the clear downregulation of total Smac/DIABLO protein level in staurosporinetreated cells (Figure 2c ), and its prevention by the proteasome inhibitor MG132 (Supplementary Figure 1) . In contrast, etoposide-treated cells presented higher cytosolic levels of Smac/DIABLO, even when no evident decrease of mitochondrial protein was found, suggesting the presence of a stabilization mechanism (Figure 2a and b). A temporal course of etoposide exposure showed that most of the cytochrome c was released by 60 h, whereas very little Smac/DIABLO was released at this time (Figure 2d and e). To eliminate the possibility that a transcriptional mechanism could explain these data, we analysed the Smac/DIABLO mRNA levels. As shown in Figure 2f , mRNA levels of the major Smac/ DIABLO isoforms remained constant during exposure to etoposide, whereas a small increase was observed after exposure to staurosporine. The defective release of Smac/DIABLO during etoposideinduced apoptosis is not due to modulation by Bcl-2 family members or caspase signaling It has been shown that etoposide exposure of cancer cells induces the accumulation of Bax in mitochondria, causing the release of cytochrome c and cell death (Karpinich et al., 2002 ). In our model, Bax accumulated in mitochondria as early as 12 h after exposure ( Figure 3a ). In addition, etoposide induced a decrease in mitochondrial Bcl-2, most noticeable at 24 h after exposure (Supplementary Figure 2) . It has been previously shown that etoposide induces a positive feedback mechanism involving active caspases and mitochondria. To assess whether this mechanism could be impaired in our model, we analysed the cleavage of caspases 8, 9 and 3 in cells exposed to etoposide. As shown in Figure 3b , caspases 9 and 3 were cleaved 24 h after exposure to the drug, in accordance with Bax translocation. These results showed that caspases were activated after Bax translocation to mitochondria and remained active during apoptosis induced by etoposide. When Bcl-2 expression was inhibited by means of antisense expression (Figure 3c ), Smac/DIABLO release from mitochondria after exposure to the LD 50 of etoposide for 48 h was not enhanced, despite the fact that a larger amount of cytochrome c was found in cytosol and a higher decrease in cell viability was induced (Figure 3d and e). Thus, our results did not support a participation of Bcl-2 family members in the delay of Smac/DIABLO release after DNA damage.
IAPs are differentially regulated by cellular stress and DNA damage When analysed, none of the detectable IAPs in HeLa cells were downregulated after DNA damage, as opposed to a clear downregulation of XIAP in cells exposed to staurosporine (Figure 4a ). Interestingly, an increase in survivin was noted in cells exposed to etoposide. These changes were not due to modulation of their mRNA levels, as demonstrated by reverse transcription (RT)-PCR analysis (Figure 4b ). It has been previously shown that survivin protein is stabilized by phosphorylation of Thr34 by p34(cdc2) (O'Connor et al., 2002) . To ascertain if p34(cdc2) was indeed responsible for the increase in survivin expression, we exposed etoposide-treated cells to olomoucine, a pharmacological inhibitor of this kinase. Figure 4c shows that this inhibitor prevented the upregulation of survivin after etoposide exposure, supporting this scenario.
Survivin is responsible for the delayed release of Smac/ DIABLO and increased cytosolic stability of Smac/ DIABLO in apoptosis induced by DNA damage Because exposure to etoposide induced a clear and specific upregulation of survivin, we sought to analyse if IAP expression in cells exposed to staurosporine and etoposide. HeLa cells were harvested after exposure to the LD 50 of staurosporine and etoposide. (a) Total proteins were subjected to immunoblotting with the indicated antibodies. *Normalized results from densitometric analyses are shown below the blot. Significative differences were found only in cells exposed to etoposide (Po0.05) (b) Steady-state XIAP, survivin and cIAP1 mRNA levels from the same cells were analysed by RT-PCR. GAPDH was used as a loading control. (c) Effect of olomoucine on survivin expression after etoposide exposure. Cells were exposed to etoposide, olomoucine or both for 14 h and total protein was analysed for survivin expression by western blot. Olomoucine, Olom. Significative differences were found only in cells exposed to etoposide **P ¼ 0.016. this protein could be responsible for the drug's effects on Smac/DIABLO. Figure 5a shows that etoposide induced the upregulation of cytosolic, nuclear and mitochondrial survivin, as opposed to staurosporine, which showed only a redistribution of survivin to the nucleus. We found a smaller increase in mitochondrial and nuclear abundance of survivin DeltaEx3 (Figure 5b ). Survivin 2B protein was undetectable in HeLa cells (data not shown). mRNA levels for all of the described survivin isoforms were not altered (Figure 5c ). These results demonstrate that the increase in survivin expression after DNA damage induced by etoposide was due to the stabilization of protein. To evaluate whether this survivin upregulation could be associated with the delayed release and stabilization of Smac/DIABLO, we used interference RNA to downregulate survivin and survivin DeltaEx3. As shown in Figure 6a and b, this approach was highly effective in reducing both survivin isoforms. When cells with reduced survivin levels were exposed to etoposide, a larger release of Smac/DIABLO from mitochondria was found, as assessed by the decrease in mitochondrial Smac/DIABLO protein (Figure 6c ). In addition, lower Smac/DIABLO protein levels were found in the cytosol of cells when survivin was downregulated. In agreement with this, a decrease in total Smac/DIABLO and XIAP proteins was observed after etoposide exposure in cells depleted of survivin (Figure 6d and Supplementary  Figure 3 ). This decrease was not due to Smac/DIABLO mRNA downregulation, as shown in Figure 6a . As expected, downregulation of survivin or DeltaEx3 isoform sensitized HeLa cells to the effects of etoposide, but not to staurosporine (Supplementary Figure 4) . Similar results were found in these cells after exposure to paclitaxel, a drug that induces the association of survivin and Smac/ DIABLO (Supplementary Figure 5) (Song et al., 2003) . These results showed that survivin and, to a lesser extent, survivin DeltaEx3 are able to delay Smac/DIABLO release from mitochondria after apoptosis induced by a genotoxic stimulus. In addition, both survivin isoforms stabilized Smac/DIABLO in the cytosol after its release.
To further support these results, we used the opposite approach, that is, increasing survivin in cells undergoing apoptosis induced by cellular stress. To achieve this, we created a stable cell line that overexpresses survivin (Figure 7a ). In these cells, the release of Smac/DIABLO following staurosporine exposure was inhibited (Figure 7b) , even considering the decrease in mitochondrial survivin levels observed after staurosporine exposure. Similarly, overexpression of survivin prevented the decrease in total Smac/DIABLO protein after staurosporine exposure (Figure 7c ). As expected, XIAP levels were maintained after staurosporine exposure when survivin was overexpressed, similar to cells exposed to etoposide (Figure 4a ). In accordance, survivin overexpression protected HeLa cells from staurosporine and blocked caspase 3 activation (Supplementary Figure 6) . Figure 6 Survivin inhibition during exposure to etoposide enhances the release of Smac/DIABLO from mitochondria and decreases its cytosolic stabilization. HeLa cells were transfected with an expression plasmid containing sequences to produce survivin-or survivin DeltaEx3-specific small interfering RNAs (siRNAs), or with a vector expressing a control siRNA. Survivinspecific (a) and survivin DeltaEx3 (survivin DEx3)-specific (b) inhibition were assessed by RT-PCR and western blotting. GAPDH was used as a loading control. (c) HeLa cells transfected with the respective siRNA vectors were exposed to etoposide for 48 h, and subjected to subcellular fractionation. Control: vector containing a scrambled survivin sequence. Mitochondrial (mit) and cytosolic (cyt) fractions were subjected to SDS-PAGE, followed by immunoblotting with the indicated antibodies. *Densitometric analysis showed significative differences (Po0.05) in cells transfected with survivin and survivin DEx3 siRNAs after exposure to etoposide (**, *) (d) HeLa cells transfected with survivin siRNA were exposed to etoposide for 48 h and total proteins were obtained and probed with anti-Smac/DIABLO. Figure 5 Survivin and survivin DeltaEx3 proteins are upregulated after etoposide exposure. HeLa cells were exposed to the LD 50 of etoposide or staurosporine. (a) Cells were subjected to subcellular fractionation. Cytosolic (cyt), mitochondrial (mit) and nuclear (nuc) fractions were subjected to SDS-PAGE, followed by immunoblotting with anti-survivin. Antibodies against actin, mitochondria (anti-mit) and nucleolin were used as loading controls. (b) HeLa cells exposed to etoposide were harvested and subjected to subcellular fractionation. Cytosolic, mitochondrial and nuclear fractions were subjected to immunoblotting with antisurvivin DeltaEx3 (survivin DEx3). *, non-specific band (c) RT-PCR analyses of survivin DeltaEx3, 2B and 3B isoforms from HeLa cells exposed to etoposide and staurosporine for 24 and 48 h, respectively. GAPDH was used as a loading control.
Smac/DIABLO binds to mitochondrial survivin Finally, we sought to investigate a direct association between mitochondrial Smac/DIABLO and survivin. Co-immunoprecipitation assays confirmed this, and as expected, showed that this association was increased after exposure to etoposide (Figure 7d ).
Discussion
Recently, it has been shown that the release of cytochrome c and Smac/DIABLO from mitochondria after apoptotic stimuli can be regulated individually. For example, Kandasamy et al. (2003) showed that after tumor necrosis factor-related apoptosis-inducing ligand exposure, Bid(À/À), Bax(À/À) or Bak(À/À) murine embryonic fibroblasts release cytochrome c, but not Smac/DIABLO. In contrast to this finding, other researchers have found that specific stimuli, such as ultraviolet light, can induce the concurrent release of cytochrome c and Smac/DIABLO (Zhou et al., 2005) . Thus, there is not yet a clear understanding of the molecular mechanism(s) for the release of these proteins.
To study the mechanism for mitochondrial intermembrane Smac/DIABLO release, we employed two apoptotic stimuli that engage the intrinsic apoptotic pathway but differ in their molecular targets. Our results showed that, although these stimuli activated the intrinsic pathway, a clear difference was found in the kinetics of Smac/DIABLO release and activation of downstream caspases. Cells exposed to etoposide presented a delayed release of this apoptotic protein when compared with those exposed to staurosporine. When we analysed the expression levels of IAPs, we found that HeLa cells exposed to etoposide presented a specific upregulation of survivin and its isoforms due to stabilization of the proteins. Similar survivin posttranslational upregulation has been found in cancer cells exposed to diverse antineoplastic agents, such as adryamicin and paclitaxel (Wall et al., 2003) , suggesting that this change in survivin expression could be a possible general effect of these drugs. Previous reports have demonstrated that survivin protein stabilization is induced by phosphorylation by p34(cdc2) (Wall et al., 2003) . Although we did not test whether survivin was phosphorylated by this kinase, exposure to olomoucine, a pharmacological inhibitor of p34(cdc2), prevented the upregulation of survivin during etoposide exposure, supporting the participation of this kinase in our model. The increase of survivin and, to a lesser extent, survivin DeltaEx3 was responsible for the delay in Smac/DIABLO release, as shown by RNA interference assays in etoposide-treated cells and survivin overexpression studies in cells exposed to staurosporine. The delayed release of Smac/DIABLO from mitochondria may be mediated by a direct union of Smac/DIABLO to mitochondrial survivin, as demonstrated by a coimmunoprecipitation assay. Survivin could be impairing the release of Smac/DIABLO by a simple size-exclusion mechanism. Previous reports have shown that survivin and cytosolic Smac/DIABLO interact during apoptosis induced by paclitaxel (Song et al., 2003) , showing that this interaction is also present in other subcellular compartments (McNeish et al., 2005) .
These results also provide an explanation for the reported contradictory results showing either a concurrent (Zhou et al., 2005) or independent (Lim et al., 2006) release of cytochrome c and Smac/DIABLO during apoptosis. Stimuli that induce an upregulation of survivin should block or delay the release of Smac/ DIABLO, even in the presence of an outer membrane permeability transition that would otherwise allow its release. Additional support to this explanation comes with our results showing an increased release of cytochrome c but not Smac/DIABLO in cells with depleted Bcl-2 (Figure 3d ).
Both the delayed release of mitochondrial Smac/ DIABLO and the blockage of cytosolic Smac/DIABLO induced by the upregulation of survivin should decrease the sensitivity of cancer cells to apoptosis and thus provide a possible mechanism for drug resistance. In support of this, it has been shown that resistance to paclitaxel in thyroid cancer cells is associated with increased survivin and reduced release of Smac/DIA-BLO from the mitochondria (Tirro et al., 2006) . Because several antineoplastic agents induce the upregulation of survivin (Ling et al., 2004; Wall et al., 2003) , it would be of interest to test whether all of these chemotherapeutic agents could equally affect the release and cytosolic activity of Smac/DIABLO. These results would provide an additional basis for the intrinsic and/or acquired resistance of cancer cells to chemotherapeutics and should help to direct future research for new therapeutic strategies.
In conclusion, in the present report we show that survivin is a key regulator of Smac/DIABLO differential release from mitochondria during apoptosis induced by DNA damage. This is accomplished by the upregulation of survivin and subsequent direct association of these two proteins in mitochondria of cells exposed to etoposide.
Materials and methods
Cell culture
HeLa cells were maintained in Dulbecco's modified Eagle's medium with 5% fetal bovine serum. Cells were cultured in a humidified incubator at 371C with 5% CO 2 .
Cell viability assays
To determine the LD 50 of staurosporine and etoposide, cells were seeded in 24-well plates and exposed to several concentrations of the relevant drug at the times indicated. After drug exposure, viability was determined using the crystal violet method (Ishiyama et al., 1996) . All experiments were performed in triplicate in three independent experiments. Induction and assessment of apoptosis Apoptosis was induced by exposure to either staurosporine at the LD 50 (250 nM) for 24 h or etoposide at the LD 50 (100 mM) for 48 h. Vehicle used in all the experiments was 0.001% dimethyl sulfoxide in phosphate-buffered saline. Nuclear morphology was assessed with ethidium bromide staining (Martinez-Velazquez et al., 2007) .
RNA isolation and RT-PCR
Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. RT-PCR were performed using the ThermoScript RT-PCR kit (Invitrogen) and Amplitaq Gold (Perkin Elmer, Waltham, MA, USA). A curve was generated for each sample to verify that the amplification reactions proceeded logarithmically. The PCR products were normalized to those obtained from glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA amplification. Gene expression measurements were repeated three times.
Western blot analysis A total of 40 mg of protein was separated by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted to polyvinylidene difluoride membranes. Blots were incubated in 0.1% (v/v) Tween-20 in TRISbuffered saline (TBS-T) with 5% nonfat dry milk (blocking solution) for 1 h at room temperature. The blots were then incubated in fresh blocking solution with the specific primary antibody at the appropriate dilution overnight at 41C. The blots were washed four times in TBS-T and then incubated with secondary horseradish peroxidase-conjugated antibodies for 1 h at room temperature. The blots were again washed and the specific bound secondary antibody visualized by enhanced chemiluminescence (Amersham Bioscience, Piscataway, NJ, USA). All the experiments were performed at least three times.
Additional information for this section is presented in the 'Supplementary Information' archive available online.
